Update cookies preferences

Free Download

EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP

Volume: 62 - Issue: 3

First page: 287 - Last page: 298

W.J. Fokkens - E. De Corso - V. Backer - M. Bernal-Sprekelsen - L. Bjermer - C. von Buchwald - A. Chaker - Z. Diamant - P. Gevaert - J. Han - C. Hopkins - V. Hox - L. Klimek - V.J. Lund - S. Lee - A. Luong - J. Mullol - A. Peters - O. Pfaar - S. Reitsma - S. Toppila-Salmi - G.K. Scadding - A.R. Sedaghat - A-S. Viskens - M. Wagenmann - P.W. Hellings

Severe chronic rhinosinusitis with nasal polyps (CRSwNP), a form of diffuse bilateral (usually type 2) CRS, is a debilitating disease
with a significant impact on quality of life (QoL). With novel knowledge and treatment options becoming available, there is a growing
need to update or revise key definitions to enable communication across different specialties dealing with CRS, and to agree
on novel goals of care in CRSwNP. The European Forum for Research and Education in Allergy and Airway diseases (EUFOREA) and
EPOS expert members discussed how to measure treatment responses and set new treatment goals for CRSwNP.
In this paper a consensus on a list of definitions related to CRSwNP is provided: control, remission, cure, recurrence/exacerbation,
treatable traits, remodeling, progression, and disease modification. By providing these definitions, the involved experts hope
to improve communication between all stakeholders involved in CRSwNP treatment for use in routine care, basic and clinical
research and international guidelines aimed to harmonize and optimize standard of care of patients with CRSwNP in the future.

Rhinology 62-3: 287-298, 0000

To see the issue content and the abstract you do not have to login

Please login to download the full articles

If you do not have a subscription to Rhinology please consider taking one.

Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, from 2024. Subscription including membership fee: Euro 135.-